The global diabetic macular edema (DME) steroids market is driven by the rising prevalence of diabetic macular edema, a common complication of diabetes. According to the International Diabetes Federation (IDF), in 2023, an estimated 537 million adults (20-79 years) were living with diabetes worldwide, and approximately 10% of these individuals are at risk of developing DME. The condition predominantly affects patients with longer durations of diabetes, with studies indicating a 3% to 7% prevalence rate among those with type 2 diabetes. Corticosteroid-based therapies have emerged as effective treatments for reducing inflammation and fluid accumulation in the macula, particularly in cases unresponsive to anti-VEGF therapies. The market is further bolstered by advancements in intravitreal implant technologies, such as dexamethasone implants, which provide sustained drug delivery and improved visual outcomes for patients. Increasing awareness and screening programs in regions with high diabetes prevalence, such as Asia-Pacific and the Middle East, are expected to enhance diagnosis and treatment rates.
